Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 35,000 shares at $48.87 ($1.7M) on 2012-11-30, disclosed to the SEC on 2012-12-04.
Scheduled sale ($1.7M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.87 | 5,000 | $244K | 14.1% |
| 2 | $49.42 | 30,000 | $1.5M | 85.9% |
| Total | $49.34 avg | 35,000 | $1.7M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |